Abvc Biopharma (ABVC) Retained Earnings (2010 - 2026)

Abvc Biopharma (ABVC) has reported Retained Earnings for 16 consecutive years, with $97.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 13.13% year-over-year to $97.7 million; the trailing twelve-month figure through Jun 2026 stood at $97.7 million (up 13.13% YoY), and the FY2025 full-year result was $96.0 million, up 22.16% from the prior year.
• Retained Earnings rose to $97.7 million in Q2 2026 per ABVC's latest filing, from $97.2 million in the prior quarter.
• Across five years, Retained Earnings topped out at $97.7 million in Q2 2026 and bottomed at $62.6 million in Q1 2022.
• Historically, Retained Earnings has averaged $79.9 million across 5 years, with a median of $79.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings soared 61.56% in 2022, then dropped 2.98% in 2024.
• Over 5 years, Retained Earnings stood at $67.9 million in 2022, then climbed by 8.89% to $74.0 million in 2023, then increased by 6.24% to $78.6 million in 2024, then climbed by 22.16% to $96.0 million in 2025, then increased by 1.79% to $97.7 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $97.7 million, $97.2 million, and $96.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.